Search
forResearch 10 of 1000+
- Association of 5-α reductase inhibitors and sexual dysfunction: A RADAR report
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases
- Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
- Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
- Assessing the safety of topical minoxidil through disproportionality analysis of FAERS reports
- Drug-associated gingival disorders: a retrospective pharmacovigilance assessment using disproportionality analysis
- PŁYNY- NIE ZA DUŻO, NIE ZA MAŁO, LECZ W SAM RAZ
- Neuropsychiatric Adverse Events of Montelukast: An Analysis of Real-World Datasets and drug−gene Interaction Network
Community 10 of 75
- Just FYI, Here are pictures of 6 months results on Clascoterone 5%. Is it remarkable? No. But it seems likely to be FDA approved considering 1% is already available. This is a win, especially if you pair it with other treatments like Finasteride.
- New warning by FDA on topical finasteride
- Dutasteride would have been approved for AGA by the US FDA.
- Finasteride alternative close to fda approval in the US
- Peeps who arent able to get gains even after using fda approved meds
- Following the recent IPO and the positive Phase 3 clinical data for VDPHL01 (extended-release oral minoxidil), what is the projected timeline for the FDA submission and the subsequent commercial availability on the market?
- FDA Policy Shift Explained: What It Actually Means for PP405, VDPHL-01, Breezula and Hair Loss Drug Timelines
- There’s actually a quite good chance that next year, we might see a new treatment get FDA approval for the first time in nearly three decades.
- Good news for stem cells hair therapies - US federal judge: using patients' stem cells does NOT fall under FDA jurisdiction
- US FDA will now default to only one clinical trial for drug applications, will this accelerate the release of PP405 and other drugs in clinical trials?
Learn
— no results
Try a deeper search in learn →